Executive Summary
Dr. Bradley T. Wyman, PhD, is a biomedical engineer and imaging scientist with more than thirty years of experience in clinical imaging, clinical trial design, management consulting, and due diligence. He works with pharmaceutical, medical device, and biotech companies to implement novel biomarkers and design studies that drive go/no-go development decisions.
His career includes ten years at Pfizer developing and implementing imaging biomarkers across therapeutic areas spanning CNS, arthritis, inflammatory disease, cardiovascular, pain, oncology, metabolic disease, and ophthalmology — including the Phase 3 bapineuzumab Alzheimer’s program and the imaging biomarker programs supporting the tofacitinib (Xeljanz) new drug application. As former Vice President of Imaging and Clinical Development at ImaginAb, he led the development and clinical testing of novel PET tracers, including the Phase 2 program for an antibody fragment directed against PSMA.
Brad brings an engineer’s mindset to clinical development: rigorous, data-driven, and focused on the decisions that move a program forward. His broader expertise includes clinical trial operations, vendor oversight, protocol and study documentation, MRI contrast agent development, data management, and software development.
Featured Podcast Episode
Brad joins Fractals, Bracken’s podcast on the strategy and the stories shaping life science.
Patents
Areas of Expertise
Imaging Biomarkers
Developing and validating imaging biomarkers (MRI, PET, X-ray, volumetric) to enable clinical decision-making across therapeutic areas from CNS to arthritis.
Clinical Trial Design
Designing studies and imaging endpoints that balance regulatory, scientific, and corporate objectives to drive clear go/no-go development decisions.
PET Tracer Development
Leading development and clinical testing of novel PET tracers and radiolabeled antibody fragments, including Phase 1 and Phase 2 oncology programs.
Clinical Development
End-to-end clinical development: protocols, investigator brochures, pharmacy manuals, CSRs, vendor and site selection, and study delivery oversight.
Due Diligence & Strategy
Evaluating novel technologies for investors and building business plans spanning development, validation, regulatory, de-risking, and financing pathways.
Medical Device & MRI Agents
MRI contrast agent development, medical device strategy, QSR / ISO 9001 / 510(k) experience, and target asset profiles for novel imaging agents.
Selected Publications
- 2025
A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson’s diseaseNeurotherapeutics · Wyman BT, Adams D, Hendrix S … Olanow CW, Kieburtz K.
- 2021
Impact of specialized light therapy in Parkinson’s disease on MDS-UPDRS parts 1–3 subscalesMov Disord · Wyman B, Hendrix S, Hennessey S … Adams D.
- 2016
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trialsAlzheimer’s Research & Therapy · Vandenberghe R, Rinne JO, Boada M, et al.
- 2016
Changes in brain volume with bapineuzumab in mild to moderate Alzheimer’s diseaseJ Alzheimer’s Disease · Novak G, Fox N, Clegg S, et al.
- 2016
Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer’s disease: amyloid imaging PET and safety results from a phase 2 studyJ Prevention of Alzheimer’s Disease · Van Dyck CH, Sadowsky C … Wyman BT, et al.
- 2016
Comparing the effects of tofacitinib, methotrexate and the combination on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritisAnnals of the Rheumatic Diseases · Conaghan PG, Østergaard M, Bowes MA, et al.